Edition:
United Kingdom

Kura Oncology Inc (KURA.OQ)

KURA.OQ on NASDAQ Stock Exchange Global Select Market

13.65USD
15 Dec 2017
Change (% chg)

$-0.10 (-0.73%)
Prev Close
$13.75
Open
$13.75
Day's High
$13.75
Day's Low
$13.40
Volume
619,585
Avg. Vol
157,495
52-wk High
$17.40
52-wk Low
$5.55

Latest Key Developments (Source: Significant Developments)

Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Kura Oncology Inc :Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​.  Full Article

Kura Oncology reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Kura Oncology Inc ::Kura Oncology reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.38.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Kura Oncology Inc :KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE.‍CONFIRMED PARTIAL RESPONSES OBSERVED IN FOUR OUT OF SIX PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL​.BASED ON POSITIVE RESULTS FROM PHASE 2 TRIAL, CO PLANS TO INITIATE A REGISTRATION-ENABLING STUDY IN HRAS MUTANT HNSCC IN 2018​.  Full Article

Kura Oncology Q2 net loss $6.7 million
Wednesday, 10 Aug 2016 

Kura Oncology Inc : Kura Oncology reports second quarter 2016 financial results . Net loss for Q2 of 2016 was $6.7 million, or $0.36 per share .Says IND Submission For Erk Inhibitor, Ko-947, is anticipated in second half of 2016.  Full Article

Kura Oncology entered amendment to license agreement with janssen pharmaceutica - SEC filing
Monday, 6 Jun 2016 

Kura Oncology Inc : Entered amendment to license agreement with Janssen Pharmaceutica NV dated December 18, 2014 - SEC filing . Amendment to expand field of license to all human diseases, disorders/medical conditions . Amendment to management services agreement with Araxes Pharma LLC to reduce the monthly management fee payable by Araxes to co .Amendment to agreement with Araxes Pharma to reduce monthly management fee from $100,000/month to $65,000/month effective from April 1,2016.  Full Article

Kura Oncology Q1 loss per share $0.36
Wednesday, 11 May 2016 

Kura Oncology Inc Says Nomination Of A Development Candidate For Menin : 947, is anticipated in q2 of 2016 . Kura oncology inc says initiation of a phase 2 clinical trial for tipifarnib in patients with cmml is anticipated in second half of 2016 . Mll program is anticipated in second half of 2016 . Kura oncology reports first quarter 2016 financial results . Q1 loss per share $0.36 .Q1 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing‍​

* Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​ Source text:(http://bit.ly/2yNnKBA) Further company coverage: